|Other Names||Probable tumor suppressor protein MN1, MN1|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Transcriptional activator which specifically regulates expression of TBX22 in the posterior region of the developing palate. Required during later stages of palate development for growth and medial fusion of the palatal shelves. Promotes maturation and normal function of calvarial osteoblasts, including expression of the osteoclastogenic cytokine TNFSF11/RANKL. Necessary for normal development of the membranous bones of the skull (By similarity). May play a role in tumor suppression (Probable).|
|Tissue Location||Ubiquitously expressed. Highest levels in skeletal muscle|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Meningioma 1 (MN1) contains two sets of CAG repeats. It isdisrupted by a balanced translocation (4;22) in a meningioma, andits inactivation may contribute to meningioma 32 pathogenesis.
Liu, T., et al. Leukemia 24(3):601-612(2010)Kandilci, A., et al. Blood 114(8):1596-1606(2009)Trynka, G., et al. Gut 58(8):1078-1083(2009)Langer, C., et al. J. Clin. Oncol. 27(19):3198-3204(2009)Schroeder, T., et al. Leuk. Lymphoma 50(6):1043-1046(2009)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.